Abstract

The response of a cell to the myriad of signals that it receives is varied, and it is dependent on many different factors. The most-studied responses involve growth-factor signalling and these signalling cascades have become key targets for cancer therapy. Recent reports have indicated that growth-factor receptors and associated adaptors can accumulate in the nucleus. Are there novel functions for these proteins that might affect our understanding of their role in cancer and have implications for drug resistance?

Author affiliations

1. Charles Massie and Ian G. Mills are at the CRUK Uro-Oncology Group, Department of Oncology, University of Cambridge, c/o Hutchison/MRC Cancer Research Centre, Addenbrookes Hospital, Hills Road, Cambridge, CB2 2XZ, UK.

Correspondence to: Ian G. Mills¹ Email: igm23@cam.ac.uk

Published online 13 April 2006

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.